Skye Bioscience gets Nasdaq bid-price notice

March 19, 2026 at 23:09 UTC

3 min read

Key Points

Skye Bioscience has fallen out of compliance with Nasdaq’s $1.00 minimum bid rule
Nasdaq has given the company until September 14, 2026, to regain compliance
Skye is considering options including a potential reverse stock split
The company’s shares continue to trade on the Nasdaq Global Market under SKYE

Nasdaq notifies Skye Bioscience of bid-price deficiency

Skye Bioscience, Inc. has received a deficiency letter from The Nasdaq Stock Market after its common stock closed below the required $1.00 minimum bid price for 30 consecutive business days. The notice indicates a failure to comply with Nasdaq Listing Rule 5450(a)(1), which governs the minimum bid price standard for continued listing on the Nasdaq Global Market.

According to an 8-K filing dated March 19, 2026, the company disclosed that the deficiency letter was received on March 17, 2026. Despite the notice, Skye Bioscience’s shares will continue to trade on the Nasdaq Global Market under the ticker symbol SKYE while the company works to regain compliance.

The bid-price deficiency does not immediately affect the company’s listing status but places it under a defined timeline and conditions to restore compliance with Nasdaq’s rules.

Compliance deadline and potential grace periods

Nasdaq has granted Skye Bioscience an initial 180-calendar-day period, until September 14, 2026, to regain compliance with the minimum $1.00 bid price requirement. To do so, the company’s stock must close at or above $1.00 per share for at least 10 consecutive business days within this period.

If Skye Bioscience does not meet the requirement by the September 14, 2026 deadline, the company may face delisting from the Nasdaq Global Market. However, one report notes that a second 180-day grace period on The Nasdaq Capital Market could be available if the company meets other applicable listing standards at that time.

The deficiency notice itself does not guarantee that Skye will regain compliance, and Nasdaq retains the authority to proceed with delisting if conditions are not satisfied within the allowed timeframe.

Company response and options under consideration

Skye Bioscience has stated that it intends to monitor the closing bid price of its common stock and evaluate available options to resolve the deficiency. Among the measures under consideration is a potential reverse stock split, which could be used to increase the per-share trading price to meet Nasdaq’s minimum bid requirement.

While a reverse stock split is identified as an option, the company has not committed to a specific course of action and has cautioned that there is no assurance it will be able to regain compliance within the prescribed period.

Market and analyst context

Despite the Nasdaq notice, Skye’s common stock continues to trade on the Nasdaq Global Market, and the company remains subject to all other applicable listing rules. The deficiency pertains solely to the minimum bid price standard under Rule 5450(a)(1).

TipRanks’ AI Analyst, Spark, currently rates Skye Bioscience as Neutral. This view is based on what is described as weak financial performance and bearish technical signals, partially offset by positive elements from recent earnings calls and Phase 2a data. This assessment provides a market-related backdrop to the company’s efforts to address the Nasdaq compliance issue.

Key Takeaways

Skye Bioscience faces a defined 180-day window in which it must lift its share price to satisfy Nasdaq’s minimum bid requirement and avoid an initial delisting risk.
The company is openly signaling that structural actions, such as a reverse stock split, are on the table but is not guaranteeing any specific outcome.
Regaining compliance depends on sustained market performance, underscored by the need for 10 consecutive business days at or above the $1.00 threshold.
Analyst commentary highlights underlying financial and technical challenges, suggesting that resolving the Nasdaq notice will require more than a short-term price move.